<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Reviva Pharmaceuticals Holdings Inc. — News on 6ix</title>
<link>https://6ix.com/company/reviva-pharmaceuticals-holdings-inc</link>
<description>Latest news and press releases for Reviva Pharmaceuticals Holdings Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/reviva-pharmaceuticals-holdings-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835bb2278dffbe2df116336.webp</url>
<title>Reviva Pharmaceuticals Holdings Inc.</title>
<link>https://6ix.com/company/reviva-pharmaceuticals-holdings-inc</link>
</image>
<item>
<title>Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine’s Potential Across Multiple Neuropsychiatric Indications</title>
<link>https://6ix.com/company/reviva-pharmaceuticals-holdings-inc/news/reviva-to-participate-in-a-fireside-chat-hosted-by-agp-on-brilaroxazines-potential-across-multiple-neuropsychiatric-indications</link>
<guid isPermaLink="true">https://6ix.com/company/reviva-pharmaceuticals-holdings-inc/news/reviva-to-participate-in-a-fireside-chat-hosted-by-agp-on-brilaroxazines-potential-across-multiple-neuropsychiatric-indications</guid>
<pubDate>Thu, 23 Apr 2026 12:00:00 GMT</pubDate>
<description>CUPERTINO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva,” the “Company” “we” or “us”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, PhD, Founder, President, and CEO of Reviva, will participate in a fireside chat hosted by A.G.P. Equity Research Analyst James</description>
</item>
<item>
<title>Reviva Announces Letter to Shareholders</title>
<link>https://6ix.com/company/reviva-pharmaceuticals-holdings-inc/news/reviva-announces-letter-to-shareholders</link>
<guid isPermaLink="true">https://6ix.com/company/reviva-pharmaceuticals-holdings-inc/news/reviva-announces-letter-to-shareholders</guid>
<pubDate>Wed, 15 Apr 2026 12:00:00 GMT</pubDate>
<description>CUPERTINO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva,” the “Company” “we” or “us”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced a letter to shareholders from Founder, President, and CEO, Laxminarayan Bhat, Ph.D. The full text of the letter follows. Dear Fellow Shareholders: The</description>
</item>
<item>
<title>Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/reviva-pharmaceuticals-holdings-inc/news/reviva-reports-full-year-2025-financial-results-and-recent-business-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/reviva-pharmaceuticals-holdings-inc/news/reviva-reports-full-year-2025-financial-results-and-recent-business-highlights</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>- Written FDA recommendations include a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for</description>
</item>
<item>
<title>Reviva Pharmaceuticals Holdings, Inc. Announces Closing of $10 Million Public Offering</title>
<link>https://6ix.com/company/reviva-pharmaceuticals-holdings-inc/news/reviva-pharmaceuticals-holdings-inc-announces-closing-of-dollar10-million-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/reviva-pharmaceuticals-holdings-inc/news/reviva-pharmaceuticals-holdings-inc-announces-closing-of-dollar10-million-public-offering</guid>
<pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
<description>CUPERTINO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage</description>
</item>
<item>
<title>Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia</title>
<link>https://6ix.com/company/reviva-pharmaceuticals-holdings-inc/news/reviva-announces-publication-clinical-vocal-130000597</link>
<guid isPermaLink="true">https://6ix.com/company/reviva-pharmaceuticals-holdings-inc/news/reviva-announces-publication-clinical-vocal-130000597</guid>
<pubDate>Thu, 08 Jan 2026 13:00:00 GMT</pubDate>
<description>Findings reinforce brilaroxazine’s treatment effect on negative symptoms and other symptom domains in schizophrenia and support clinician-assessed efficacy outcomes in a Phase 3 trial of brilaroxazine Findings also support use of speech latency as an enrichment tool that can reduce sample-size and enhance outcomes in clinical trials for schizophrenia CUPERTINO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage</description>
</item>
<item>
<title>Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum</title>
<link>https://6ix.com/company/reviva-pharmaceuticals-holdings-inc/news/reviva-present-sachs-9th-annual-130000652</link>
<guid isPermaLink="true">https://6ix.com/company/reviva-pharmaceuticals-holdings-inc/news/reviva-present-sachs-9th-annual-130000652</guid>
<pubDate>Mon, 29 Dec 2025 13:00:00 GMT</pubDate>
<description>CUPERTINO, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the Sachs 9th Annual Neuroscience Innovation Forum, taking place January 11, 2026,</description>
</item>
<item>
<title>Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia</title>
<link>https://6ix.com/company/reviva-pharmaceuticals-holdings-inc/news/reviva-announces-regulatory-regarding-development-130000072</link>
<guid isPermaLink="true">https://6ix.com/company/reviva-pharmaceuticals-holdings-inc/news/reviva-announces-regulatory-regarding-development-130000072</guid>
<pubDate>Tue, 23 Dec 2025 13:00:00 GMT</pubDate>
<description>Written feedback from FDA pre-NDA meeting includes a recommendation to conduct a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for the treatment of schizophrenia Current data package highlights long-term safety profile, broad-spectrum clinical activity, and favorable adherence observed to date for once daily brilaroxazine over up to one year Initiation of RECOVER-2 registrational trial planned in H1 2026, subject to sufficient finan</description>
</item>
<item>
<title>Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/reviva-pharmaceuticals-holdings-inc/news/reviva-reports-third-quarter-2025-210500513</link>
<guid isPermaLink="true">https://6ix.com/company/reviva-pharmaceuticals-holdings-inc/news/reviva-reports-third-quarter-2025-210500513</guid>
<pubDate>Thu, 13 Nov 2025 21:05:00 GMT</pubDate>
<description>– Pre-NDA meeting with FDA to discuss brilaroxazine’s path to approval for schizophrenia planned in Q4 2025 – – Potential NDA submission for schizophrenia indication targeted for Q2 2026 – – European patent granted covering use of brilaroxazine for the treatment of pulmonary fibrosis adds to existing patent protection in key global markets – CUPERTINO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmace</description>
</item>
<item>
<title>Reviva to Present Anti-Inflammatory Impacts of Brilaroxazine in Schizophrenia from the RECOVER 12-month Open Label Extension Trial at Neuroscience 2025</title>
<link>https://6ix.com/company/reviva-pharmaceuticals-holdings-inc/news/reviva-present-anti-inflammatory-impacts-130000146</link>
<guid isPermaLink="true">https://6ix.com/company/reviva-pharmaceuticals-holdings-inc/news/reviva-present-anti-inflammatory-impacts-130000146</guid>
<pubDate>Wed, 12 Nov 2025 13:00:00 GMT</pubDate>
<description>CUPERTINO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that the anti-inflammatory impacts of brilaroxazine from the Phase 3 RECOVER double-blind trial in patients with acute exacerbation of schizophrenia, and from the</description>
</item>
<item>
<title>Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Fibrosis</title>
<link>https://6ix.com/company/reviva-pharmaceuticals-holdings-inc/news/reviva-announces-grant-european-patent-130000603</link>
<guid isPermaLink="true">https://6ix.com/company/reviva-pharmaceuticals-holdings-inc/news/reviva-announces-grant-european-patent-130000603</guid>
<pubDate>Mon, 10 Nov 2025 13:00:00 GMT</pubDate>
<description>- Patent covers brilaroxazine use for treating Pulmonary Fibrosis -Similar patents have also been granted in key markets around the world including the United States, China, and Japan -Brilaroxazine has a novel mechanism of action for treating the underlying disruption in serotonin signaling implicated in the pathogenesis of Pulmonary Fibrosis CUPERTINO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharma</description>
</item>
<item>
<title>Reviva to Participate in the Spartan Capital Securities Second Annual Investor Conference</title>
<link>https://6ix.com/company/reviva-pharmaceuticals-holdings-inc/news/reviva-participate-spartan-capital-securities-120000959</link>
<guid isPermaLink="true">https://6ix.com/company/reviva-pharmaceuticals-holdings-inc/news/reviva-participate-spartan-capital-securities-120000959</guid>
<pubDate>Wed, 29 Oct 2025 12:00:00 GMT</pubDate>
<description>CUPERTINO, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in Spartan Capital Securities Second Annual Investor Conference on November</description>
</item>
<item>
<title>Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025</title>
<link>https://6ix.com/company/reviva-pharmaceuticals-holdings-inc/news/reviva-present-negative-symptom-data-120000323</link>
<guid isPermaLink="true">https://6ix.com/company/reviva-pharmaceuticals-holdings-inc/news/reviva-present-negative-symptom-data-120000323</guid>
<pubDate>Tue, 28 Oct 2025 12:00:00 GMT</pubDate>
<description>CUPERTINO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that negative symptom data for brilaroxazine from the Phase 3 RECOVER double-blind trial in patients with acute exacerbation of schizophrenia, and from the long-t</description>
</item>
<item>
<title>Reviva to Participate in Key Opinion Leader Webinar Hosted by Alliance Global Partners</title>
<link>https://6ix.com/company/reviva-pharmaceuticals-holdings-inc/news/reviva-participate-key-opinion-leader-200800315</link>
<guid isPermaLink="true">https://6ix.com/company/reviva-pharmaceuticals-holdings-inc/news/reviva-participate-key-opinion-leader-200800315</guid>
<pubDate>Tue, 07 Oct 2025 20:08:00 GMT</pubDate>
<description>CUPERTINO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, PhD, Founder, President, and CEO of Reviva will participate in a fireside chat and key opinion leader (KOL) webinar hosted by A.G.P./Allia</description>
</item>
<item>
<title>Reviva to Participate in the 4th Annual Roth Healthcare Opportunities Conference</title>
<link>https://6ix.com/company/reviva-pharmaceuticals-holdings-inc/news/reviva-participate-4th-annual-roth-120000276</link>
<guid isPermaLink="true">https://6ix.com/company/reviva-pharmaceuticals-holdings-inc/news/reviva-participate-4th-annual-roth-120000276</guid>
<pubDate>Thu, 02 Oct 2025 12:00:00 GMT</pubDate>
<description>CUPERTINO, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in panel discussion and host one-on-one investor meetings at the 4th Annual</description>
</item>
<item>
<title>Reviva to Participate in the Lytham Partners Fall 2025 Investor Conference</title>
<link>https://6ix.com/company/reviva-pharmaceuticals-holdings-inc/news/reviva-participate-lytham-partners-fall-120000504</link>
<guid isPermaLink="true">https://6ix.com/company/reviva-pharmaceuticals-holdings-inc/news/reviva-participate-lytham-partners-fall-120000504</guid>
<pubDate>Tue, 23 Sep 2025 12:00:00 GMT</pubDate>
<description>CUPERTINO, Calif., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present and host one-on-one investor meetings at the Lytham Partners Fall 2025 Investor</description>
</item>
<item>
<title>Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $9 Million Public Offering</title>
<link>https://6ix.com/company/reviva-pharmaceuticals-holdings-inc/news/reviva-pharmaceuticals-holdings-inc-announces-012600796</link>
<guid isPermaLink="true">https://6ix.com/company/reviva-pharmaceuticals-holdings-inc/news/reviva-pharmaceuticals-holdings-inc-announces-012600796</guid>
<pubDate>Fri, 19 Sep 2025 01:26:00 GMT</pubDate>
<description>CUPERTINO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced the pricing of its previously announced public offering with existing and new healthcare focused institutional investors for the purchase and sale of 27,000,000</description>
</item>
<item>
<title>Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering</title>
<link>https://6ix.com/company/reviva-pharmaceuticals-holdings-inc/news/reviva-pharmaceuticals-holdings-inc-announces-200500461</link>
<guid isPermaLink="true">https://6ix.com/company/reviva-pharmaceuticals-holdings-inc/news/reviva-pharmaceuticals-holdings-inc-announces-200500461</guid>
<pubDate>Thu, 18 Sep 2025 20:05:00 GMT</pubDate>
<description>CUPERTINO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that it intends to offer shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase shares of common stock in a public off</description>
</item>
<item>
<title>Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/reviva-pharmaceuticals-holdings-inc/news/reviva-reports-second-quarter-2025-202500369</link>
<guid isPermaLink="true">https://6ix.com/company/reviva-pharmaceuticals-holdings-inc/news/reviva-reports-second-quarter-2025-202500369</guid>
<pubDate>Thu, 14 Aug 2025 20:25:00 GMT</pubDate>
<description>– Well-tolerated safety profile and robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms in open label extension (OLE) 1-year trial– – Successful completion of two large randomized double-blind clinical trials, including one Phase 2 and one Phase 3 trial, a 1-year OLE trial, and clinical pharmacology studies designed to support filing of New Drug Application (NDA) – – Planned meeting with Food and Drug Administration (FDA) to discuss brilaro</description>
</item>
<item>
<title>Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering</title>
<link>https://6ix.com/company/reviva-pharmaceuticals-holdings-inc/news/reviva-pharmaceuticals-holdings-inc-announces-124000446</link>
<guid isPermaLink="true">https://6ix.com/company/reviva-pharmaceuticals-holdings-inc/news/reviva-pharmaceuticals-holdings-inc-announces-124000446</guid>
<pubDate>Thu, 26 Jun 2025 12:40:00 GMT</pubDate>
<description>CUPERTINO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced the pricing of its previously announced public offering with existing and new healthcare focused institutional investors for the purchase and sale of 20,000,000 s</description>
</item>
<item>
<title>Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference</title>
<link>https://6ix.com/company/reviva-pharmaceuticals-holdings-inc/news/reviva-participate-h-c-wainwright-120000020</link>
<guid isPermaLink="true">https://6ix.com/company/reviva-pharmaceuticals-holdings-inc/news/reviva-participate-h-c-wainwright-120000020</guid>
<pubDate>Thu, 05 Jun 2025 12:00:00 GMT</pubDate>
<description>CUPERTINO, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference, taking p</description>
</item>
</channel>
</rss>